14.66
-0.05 (-0.34%)
| Previous Close | 14.71 |
| Open | 14.95 |
| Volume | 527,991 |
| Avg. Volume (3M) | 881,912 |
| Market Cap | 1,196,138,752 |
| Price / Sales | 3.54 |
| Price / Book | 2.88 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -130,369.45% |
| Diluted EPS (TTM) | -3.35 |
| Total Debt/Equity (MRQ) | 3.82% |
| Current Ratio (MRQ) | 19.49 |
| Operating Cash Flow (TTM) | -279.75 M |
| Levered Free Cash Flow (TTM) | -171.41 M |
| Return on Assets (TTM) | -32.62% |
| Return on Equity (TTM) | -51.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Viridian Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 114.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Commodore Capital Lp | 31 Mar 2025 | 3,600,000 |
| Fairmount Funds Management Llc | 31 Mar 2025 | 3,445,813 |
| Novo Holdings A/S | 31 Mar 2025 | 2,250,300 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (RBC Capital, 206.96%) | Buy |
| Median | 36.00 (145.57%) | |
| Low | 27.00 (Goldman Sachs, 84.18%) | Buy |
| Average | 36.00 (145.57%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 12.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 20 May 2025 | 36.00 (145.57%) | Buy | 13.82 |
| 07 May 2025 | 36.00 (145.57%) | Buy | 12.29 | |
| Goldman Sachs | 07 May 2025 | 27.00 (84.17%) | Buy | 12.29 |
| JMP Securities | 07 May 2025 | 38.00 (159.21%) | Buy | 12.29 |
| RBC Capital | 07 May 2025 | 45.00 (206.96%) | Buy | 12.29 |
| HC Wainwright & Co. | 23 Apr 2025 | 34.00 (131.92%) | Buy | 13.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Jun 2025 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 30 May 2025 | Announcement | Viridian Therapeutics to Participate in Upcoming June Investor Conferences |
| 20 May 2025 | Announcement | Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) |
| 07 May 2025 | Announcement | Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) |
| 06 May 2025 | Announcement | Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results |
| 02 May 2025 | Announcement | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Apr 2025 | Announcement | Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |